Home
About IRMND
News
Seminars
Articles
Instruction
Contact us
 
 
 
 
 
 
 

FDA approves first anti-chorea drug
Researchers from the Feinstein Institute of Medical Research in New York claim that the effectiveness of the drug has been confirmed in a randomized, double-blind, placebo-controlled multicenter clinical trial and can considerably improve the quality of life in patients suffering from Huntington's disease.

Prestwick-made tetrabenazine controls involuntary movements, known as chorea, by reducing the brain levels of dopamine, a neurotransmitter that helps control nerve cells.

The drug, however, can worsen one's mood, cognition and mental function in the long term. Other side effects include rigidity, insomnia, drowsiness, restlessness and nausea.

Huntington's disease is an inherited, progressive, degenerative neurological disorder that causes certain nerve cells in the brain to waste away, resulting in uncontrolled movements, emotional disturbances and mental deterioration. Chorea is the involuntary jerky movement that is a hallmark of the condition.
 
Copyright © IRNMD 2013. All Rights Reserved